191 related articles for article (PubMed ID: 34913485)
1. Adult T-cell leukemia-lymphoma acquires resistance to DNA demethylating agents through dysregulation of enzymes involved in pyrimidine metabolism.
Yoshida-Sakai N; Watanabe T; Yamamoto Y; Ureshino H; Kamachi K; Kurahashi Y; Fukuda-Kurahashi Y; Kimura S
Int J Cancer; 2022 Apr; 150(7):1184-1197. PubMed ID: 34913485
[TBL] [Abstract][Full Text] [Related]
2. Targeting aberrant DNA hypermethylation as a driver of ATL leukemogenesis by using the new oral demethylating agent OR-2100.
Watanabe T; Yamashita S; Ureshino H; Kamachi K; Kurahashi Y; Fukuda-Kurahashi Y; Yoshida N; Hattori N; Nakamura H; Sato A; Kawaguchi A; Sueoka-Aragane N; Kojima K; Okada S; Ushijima T; Kimura S; Sueoka E
Blood; 2020 Aug; 136(7):871-884. PubMed ID: 32391874
[TBL] [Abstract][Full Text] [Related]
3. Dual targeting of aberrant DNA and histone methylation synergistically suppresses tumor cell growth in ATL.
Kurahashi Y; Watanabe T; Yamamoto Y; Ureshino H; Kamachi K; Yoshida-Sakai N; Fukuda-Kurahashi Y; Yamashita S; Hattori N; Nakamura H; Kawaguchi A; Ushijima T; Sueoka E; Kimura S
Blood Adv; 2023 Apr; 7(8):1545-1559. PubMed ID: 36516085
[TBL] [Abstract][Full Text] [Related]
4. Reprogramming of pyrimidine nucleotide metabolism supports vigorous cell proliferation of normal and malignant T cells.
Watanabe T; Yamamoto Y; Kurahashi Y; Kawasoe K; Kidoguchi K; Ureshino H; Kamachi K; Yoshida-Sakai N; Fukuda-Kurahashi Y; Nakamura H; Okada S; Sueoka E; Kimura S
Blood Adv; 2024 Mar; 8(6):1345-1358. PubMed ID: 38190613
[TBL] [Abstract][Full Text] [Related]
5. Combination of azacytidine and curcumin is a potential alternative in decitabine-resistant colorectal cancer cells with attenuated deoxycytidine kinase.
Hosokawa M; Seiki R; Iwakawa S; Ogawara KI
Biochem Biophys Res Commun; 2021 Nov; 578():157-162. PubMed ID: 34571370
[TBL] [Abstract][Full Text] [Related]
6. In vitro-induced resistance to the deoxycytidine analogues cytarabine (AraC) and 5-aza-2'-deoxycytidine (DAC) in a rat model for acute myeloid leukemia is mediated by mutations in the deoxycytidine kinase (dck) gene.
Stegmann AP; Honders MW; Hagemeijer A; Hoebee B; Willemze R; Landegent JE
Ann Hematol; 1995 Jul; 71(1):41-7. PubMed ID: 7543292
[TBL] [Abstract][Full Text] [Related]
7. Mechanisms of resistance to 5-aza-2'-deoxycytidine in human cancer cell lines.
Qin T; Jelinek J; Si J; Shu J; Issa JP
Blood; 2009 Jan; 113(3):659-67. PubMed ID: 18931345
[TBL] [Abstract][Full Text] [Related]
8. De novo induced mutations in the deoxycytidine kinase (dck) gene in rat leukemic clonal cell lines confer resistance to cytarabine (AraC) and 5-aza-2'-deoxycytidine (DAC).
Stegmann AP; Honders MW; Willemze R; Landegent JE
Leukemia; 1995 Jun; 9(6):1032-8. PubMed ID: 7541096
[TBL] [Abstract][Full Text] [Related]
9. A comparison of azacitidine and decitabine activities in acute myeloid leukemia cell lines.
Hollenbach PW; Nguyen AN; Brady H; Williams M; Ning Y; Richard N; Krushel L; Aukerman SL; Heise C; MacBeth KJ
PLoS One; 2010 Feb; 5(2):e9001. PubMed ID: 20126405
[TBL] [Abstract][Full Text] [Related]
10. Decitabine- and 5-azacytidine resistance emerges from adaptive responses of the pyrimidine metabolism network.
Gu X; Tohme R; Tomlinson B; Sakre N; Hasipek M; Durkin L; Schuerger C; Grabowski D; Zidan AM; Radivoyevitch T; Hong C; Carraway H; Hamilton B; Sobecks R; Patel B; Jha BK; Hsi ED; Maciejewski J; Saunthararajah Y
Leukemia; 2021 Apr; 35(4):1023-1036. PubMed ID: 32770088
[TBL] [Abstract][Full Text] [Related]
11. Mechanisms of resistance to decitabine in the myelodysplastic syndrome.
Qin T; Castoro R; El Ahdab S; Jelinek J; Wang X; Si J; Shu J; He R; Zhang N; Chung W; Kantarjian HM; Issa JP
PLoS One; 2011; 6(8):e23372. PubMed ID: 21858090
[TBL] [Abstract][Full Text] [Related]
12. Monophosphorylation by deoxycytidine kinase affects apparent cellular uptake of decitabine in HCT116 colon cancer cells.
Ueda K; Masuda A; Fukuda M; Tanaka S; Hosokawa M; Iwakawa S
Drug Metab Pharmacokinet; 2017 Dec; 32(6):301-310. PubMed ID: 29174536
[TBL] [Abstract][Full Text] [Related]
13. Changes in Apoptotic Pathways in MOLM-13 Cell Lines after Induction of Resistance to Hypomethylating Agents.
Janotka Ľ; Messingerová L; Šimoničová K; Kavcová H; Elefantová K; Sulová Z; Breier A
Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33669837
[TBL] [Abstract][Full Text] [Related]
14. Silylation of Deoxynucleotide Analog Yields an Orally Available Drug with Antileukemia Effects.
Ureshino H; Kurahashi Y; Watanabe T; Yamashita S; Kamachi K; Yamamoto Y; Fukuda-Kurahashi Y; Yoshida-Sakai N; Hattori N; Hayashi Y; Kawaguchi A; Tohyama K; Okada S; Harada H; Ushijima T; Kimura S
Mol Cancer Ther; 2021 Aug; 20(8):1412-1421. PubMed ID: 34045225
[TBL] [Abstract][Full Text] [Related]
15. Role of deoxycytidine kinase in an in vitro model for AraC- and DAC-resistance: substrate-enzyme interactions with deoxycytidine, 1-beta-D-arabinofuranosylcytosine and 5-aza-2'-deoxycytidine.
Stegmann AP; Honders MW; Kester MG; Landegent JE; Willemze R
Leukemia; 1993 Jul; 7(7):1005-11. PubMed ID: 7686601
[TBL] [Abstract][Full Text] [Related]
16. Smac mimetic and demethylating agents synergistically trigger cell death in acute myeloid leukemia cells and overcome apoptosis resistance by inducing necroptosis.
Steinhart L; Belz K; Fulda S
Cell Death Dis; 2013 Sep; 4(9):e802. PubMed ID: 24030154
[TBL] [Abstract][Full Text] [Related]
17. Decitabine induces delayed reactive oxygen species (ROS) accumulation in leukemia cells and induces the expression of ROS generating enzymes.
Fandy TE; Jiemjit A; Thakar M; Rhoden P; Suarez L; Gore SD
Clin Cancer Res; 2014 Mar; 20(5):1249-58. PubMed ID: 24423613
[TBL] [Abstract][Full Text] [Related]
18. Resistance of Leukemia Cells to 5-Azacytidine: Different Responses to the Same Induction Protocol.
Šimoničová K; Janotka L; Kavcova H; Sulova Z; Messingerova L; Breier A
Cancers (Basel); 2023 Jun; 15(11):. PubMed ID: 37297025
[TBL] [Abstract][Full Text] [Related]
19. Importance of dose-schedule of 5-aza-2'-deoxycytidine for epigenetic therapy of cancer.
Lemaire M; Chabot GG; Raynal NJ; Momparler LF; Hurtubise A; Bernstein ML; Momparler RL
BMC Cancer; 2008 May; 8():128. PubMed ID: 18454857
[TBL] [Abstract][Full Text] [Related]
20. Transfection of wild-type deoxycytidine kinase (dck) cDNA into an AraC- and DAC-resistant rat leukemic cell line of clonal origin fully restores drug sensitivity.
Stegmann AP; Honders WH; Willemze R; Ruiz van Haperen VW; Landegent JE
Blood; 1995 Mar; 85(5):1188-94. PubMed ID: 7532033
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
